TORONTO, Nov. 19, 2013 /PRNewswire/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical
technologies company, will showcase new products at MEDICA the
world's largest medical technology trade fair, November 20 to 23 in Düsseldorf, Germany.
Brian Pedlar, Covalon's Chief
Executive Officer said, "Since we announced the transformative
license agreement with Molnlycke earlier this month, the amount of
interest in our new product pipeline has spiked
significantly. As a result, we have accelerated the unveiling
of our FDA-cleared ColActive® Transfer wound
dressing and our CovaCoat™ A.I. Anti Infective coatings.
Along with our proven ColActive® Plus wound
dressings and SilverCoat™ Antimicrobial Foley Catheters, our strong
pipeline of new products and technologies, which includes
ColActive® Transfer and CovaCoat™ A.I., positions
Covalon well as a partner for wound care, urological, vascular
access, surgical and orthopaedic companies and distributors."
The latest addition to the patented ColActive™ family of wound
care products being showcased at MEDICA is
ColActive® Transfer, Covalon's bio-degradable
wound dressing that stimulates wound healing responses in difficult
to heal wounds, while allowing wound fluids to pass through the
dressing. ColActive® Transfer is designed
to protect new-growth tissue in wounds undergoing treatment and is
FDA approved for sale in the United
States. Along with the introduction of
ColActive® Transfer, Covalon anticipates entering
the nearly US$500 million negative
pressure dressing and kit market.
Covalon will also be unveiling its new patented CovaCoat™ A.I.
Anti Infective coating technology that provides antimicrobial and
anti-thrombogenic properties, without eluting antimicrobial agents
from the surface of medical devices. Covalon's CovaCoat™ A.I. Anti
Infective Foley Catheter significantly reduces biofilm formation on
urinary catheters, the formation of which is a major source of
hospital acquired infections. The use of CovaCoat™ A.I. on
vascular access devices provides both anti-thrombogenic and
antimicrobial characteristics without the downside of delivering
potentially cytotoxic antimicrobial agents directly into the
bloodstream.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes
new healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used
to prevent, detect and manage medical conditions in specialty areas
such as wound care, tissue repair, infection control, disease
management, medical device coatings and biocompatibility. To learn
more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.